NKGen Biotech Company Description

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies.

Its lead products include SNK01, an autologous NK cell therapy candidate treatment for neurodegenerative diseases; and SNK02, an allogeneic NK cell therapy, which is in Phase 1 clinical trials for refractory solid tumors.

The company has a license agreement with NKMAX. The company was formerly known as NKMAX America, Inc. NKGen Biotech, Inc. was founded in 2017 and is headquartered in Santa Ana, California.

NKGen Biotech, Inc.

Country	United States
Founded	2017
Industry	Biotechnology
Sector	Healthcare
Employees	63
CEO	Paul Y. Song

Contact Details

Address: 3001 Daimler Street Santa Ana, Delaware 92705 United States
Phone	949-396-6830
Website	nkgenbiotech.com

Stock Details

Ticker Symbol	NKGN
Exchange	OTCMKTS
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
ISIN Number	US65488A1016
SIC Code	2836

Key Executives

Name	Position
Dr. Paul Y. Song M.D.	Chief Executive Officer and Chairman
Dr. Yong Man Kim Ph.D.	Chief Scientific Officer
James A. Graf	Interim Chief Financial Officer
Yoonmi Kang	SVice President of Technical Ops and Development
Irene Chang	SVice President, Human Resources and Corporate Culture
Denise A. Chua CLS, MBA, MT (ASCP)	SVice President of Corporate Affairs
Ryan Park C.F.A.	Executive Vice President of FP&A, Corporate Planning and Strategy